Related Experiment Video
Updated: Jul 14, 2026

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport
Published on: November 27, 2016
Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux
M Marcil1, A Brooks-Wilson, S M Clee
1Xenon Bioresearch Inc, NRC Innovation Centre, Vancouver, British Columbia, Canada.
Insights
Mutations in the ATP-binding-cassette (ABC1) gene cause familial high-density lipoprotein (HDL) deficiency by impairing cellular cholesterol efflux. This highlights ABC1 modulation as a potential strategy for increasing HDL levels.
Area of Science:
- Genetics and Molecular Biology
- Cardiovascular Research
- Metabolic Disorders
Background:
- Low high-density lipoprotein (HDL) cholesterol is common in premature atherosclerosis.
- Tangier disease, a severe HDL deficiency, results from mutations in the ATP-binding-cassette (ABC1) gene, which encodes cholesterol-efflux regulatory protein (CERP).
Purpose of the Study:
- To investigate mutations in the ABC1 gene in patients with familial HDL deficiency.
Main Methods:
- Studied three French-Canadian and one Dutch family with familial HDL deficiency.
- Analyzed fibroblast cholesterol efflux and sequenced the ABC1 gene's coding region.
- Used PCR and RFLP assays to track mutations within families and in controls.
Main Results:
- Identified distinct ABC1 mutations in each family, leading to CERP truncation or altered amino acid residues.
- All identified mutations segregated with low HDL-cholesterol levels.
- No mutations were found in over 500 control chromosomes.
Conclusions:
- ABC1 mutations are a primary cause of familial HDL deficiency linked to impaired cholesterol efflux.
- CERP plays a critical role in HDL formation.
- Modulating ABC1 offers a potential therapeutic approach to increase HDL concentrations.
Background:
A low concentration of HDL cholesterol is the most common lipoprotein abnormality in patients with premature atherosclerosis. We have shown that Tangier disease, a rare and severe form of HDL deficiency characterised by a biochemical defect in cellular cholesterol efflux, is caused by mutations in the ATP-binding-cassette (ABC1) gene. This gene codes for the cholesterol-efflux regulatory protein (CERP). We investigated the presence of mutations in this gene in patients with familial HDL deficiency.
Methods:
Three French-Canadian families and one Dutch family with familial HDL deficiency were studied. Fibroblasts from the proband of each family were defective in cellular cholesterol efflux. Genomic DNA of each proband was used for mutation detection with primers flanking each exon of the ABC1 gene, and for sequencing of the entire coding region of the gene. PCR and restriction-fragment length polymorphism assays specific to each mutation were used to investigate segregation of the mutation in each family, and to test for absence of the mutation in DNA from normal controls.
Findings:
A different mutation was detected in ABC1 in each family studied. Each mutation either created a stop codon predicted to result in truncation of CERP, or altered a conserved aminoacid residue. Each mutation segregated with low concentrations of HDL-cholesterol in the family, and was not observed in more than 500 control chromosomes tested.
Interpretation:
These data show that mutations in ABC1 are the major cause of familial HDL deficiency associated with defective cholesterol efflux, and that CERP has an essential role in the formation of HDL. Our findings highlight the potential of modulation of ABC1 as a new route for increasing HDL concentrations.
Related Concept Videos
ABC Transporters: Exporter
ABC Transporters: Importer
In bacteria, based on the number of transmembrane helices and the chemical nature of their substrates, the ABC importers can be divided into three types:
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenomics: Identification of New Drug Targets

